Asymchem rides CRO rally, but profit drop and FX hit temper gains
CRO sector rally lifts Asymchem A broad CRO sector surge, sparked by WuXi AppTec's strong half-year results and raised guidance, pushed Asymchem and peers to daily limit-up. This reflects renewed demand for drug R&D outsourcing, which supports Asymchem's order book and future revenue.
Explains the main positive force behind the stock's recent price moves.
AsymBio secures major investment Asymchem Group and Hillhouse Qirui are investing 1.24 billion yuan in AsymBio, a biologics CDMO subsidiary. This capital injection supports capacity expansion and growth in high-growth areas like ADCs, strengthening Asymchem's long-term competitive position.
Shows a concrete capital commitment that boosts growth prospects.
First-half profit falls despite revenue growth Asymchem's first-half net profit dropped 15.7% year on year to 520 million yuan, even as revenue rose 13.1%. The decline was mainly due to currency swings; excluding FX effects, adjusted profit rose 12.9%. The headline miss may pressure the stock short-term.
Directly addresses the earnings miss that weighs on investor sentiment.
Backlog surges over 50%, signaling strong demand Asymchem's total orders on hand jumped 53.8% year on year to $1.67 billion, with new orders up 54.6%. This strong backlog, especially in emerging businesses like chemical and biological macromolecule CDMO, points to robust future revenue growth and supports the stock's valuation.
Highlights a key forward-looking indicator that offsets profit concerns.